Somahlution announced the presentation of new data showing the its DuraGraft vascular graft treatment significantly improves long-term outcomes in coronary artery bypass grafting (CABG) surgery. Results were presented today at the European Association for Cardio-Thoracic Surgery (EACTS) annual meeting in Barcelona, Spain.
The retrospective, non-randomised study conducted at VA Boston Healthcare System (MAVERIC) evaluated the real-world evidence of DuraGraft use in a total of 2,436 consecutive patients who underwent CABG surgery with at least one saphenous vein graft. DuraGraft vascular graft treatment was associated with statistically significant lower risks for non-fatal myocardial infarction, repeat revascularization, and a composite of all major adverse cardiac events (MACE) over 12+ years of patient follow up.
The risk of myocardial infarction beginning as early as 30 days following surgery was reduced by 36% (p=0.0003). This treatment effect on myocardial infarction rate was even more pronounced beginning at three years following surgery, with an adjusted risk reduction of 50% (p=0.0001). DuraGraft treatment also provided 38% long-term reductions in the need for repeat revascularisation (p=0.03) and a 29% reduction in the occurrence of all MACEs (p=0.02).
The lead investigator of the study, Miguel Haime, comments: “These new findings highlight that the protective effects of DuraGraft treatment present significant advantages in long-term clinical follow up post-CABG surgery. These results provide further supporting evidence indicating the importance of graft treatment during surgery and its potentially significant role in reducing graft failure for thousands of CABG patients each year.”
According to a press release, DuraGraft is a first-in-class vascular graft treatment designed to prevent vein graft failure post-CABG by effectively treating the graft during surgery.
